Auti Swapnil S, Thakar Anup B, Shukla Vinay J, Ravishankar B
Ph.D. Scholar, Department of Panchakarma, Gujarat Ayurved University, Jamnagar, Gujarat, India.
Associate Professor and I/C Head, Department of Panchakarma, Gujarat Ayurved University, Jamnagar, Gujarat, India.
Ayu. 2013 Oct;34(4):339-45. doi: 10.4103/0974-8520.127683.
Hyperlipidemia is highly prevalent and is closely related to coronary heart disease which is the most common cause of death. Raised cholesterol is estimated to be responsible for 18% of cerebrovascular disease and 56% of ischemic heart disease. Overall, these diseases account for about 4.4 million deaths (7.9% of the total). Based upon the etiological factors and symptom complexes, hyperlipidemia can be considered as a part of Medoroga. Being a Tikshna formulation, the treatment modality of Lekhana Basti is aimed basically for Apatarpana (emaciation) of the body, as Basti is the fastest Apatarpana. In the present clinical trial, a total of 22 patients were registered of whom 19 patients completed the course of the therapy. Under randomization, the registered patients were divided into two groups of which group A was treated with Lekhana Basti and group B was administered standard control drug, i.e., Triphala Guggulu, for 21 days. The results of the study revealed that in patients treated with Lekhana Basti, there was a decrease of about 4.99% in S. cholesterol, 9.13% in S. low density lipoprotein (LDL), and 0.36% in S. apolipoprotein B. Lekhana Basti was found to have significant effect in reducing the symptoms of Medodushti and in reduction of objective parameters like weight, body mass index (BMI), body fat percentage, body circumferences such as chest, abdomen, hip, pelvis, mid-thigh circumference, etc., and skin fold thickness as biceps, triceps, mid-arm, and abdominal skinfold thickness.
高脂血症非常普遍，且与冠心病密切相关，而冠心病是最常见的死亡原因。据估计，胆固醇升高导致18%的脑血管疾病和56%的缺血性心脏病。总体而言，这些疾病导致约440万人死亡（占总死亡人数的7.9%）。基于病因和症状复合体，高脂血症可被视为Medoroga的一部分。作为一种强效配方，利哈纳灌肠疗法的治疗方式主要旨在使身体消瘦，因为灌肠是最快的消瘦方法。在本临床试验中，共登记了22名患者，其中19名患者完成了治疗疗程。在随机分组下，登记的患者被分为两组，其中A组接受利哈纳灌肠治疗，B组服用标准对照药物三果古古卢，为期21天。研究结果显示，接受利哈纳灌肠治疗的患者中，血清胆固醇降低了约4.99%，血清低密度脂蛋白（LDL）降低了9.13%，血清载脂蛋白B降低了0.36%。发现利哈纳灌肠在减轻Medodushti症状以及降低体重、体重指数（BMI）、体脂百分比、胸围、腹围、臀围、骨盆围、大腿中部围等身体周长以及肱二头肌、肱三头肌、上臂中部和腹部皮褶厚度等皮褶厚度等客观参数方面具有显著效果。
